The funds will be used to advance the company's voyageR^™ discovery platform, which integrates machine learning and RNA exploration at scale to identify novel RNA targets and RNA-targeting small molecule drugs. Launched in May 2021, ReviR's mission is to harness machine learning as well as advanced RNA technologies in order to develop novel medicines for treating human disease.

The round was led by 5Y Capital (formerly Morningside Venture Capital) and CDH Investments, with participation from additional investors, including Shunwei Capital, Sky9 Capital, and Tiantu Capital. 

"ReviR aims to establish a world-class RNA therapeutics company empowered by AI and a deeper understanding of the complex life cycle of RNA. This Pre-A financing allows us to expand our existing research team of ~25 wet/dry lab scientists and to further develop our AI-driven target and drug discovery platforms," said Peng Yue, Ph.D., co-founder and CEO of ReviR.

"Combined with high-throughput experimental assays, the application of AI and computation is re-defining drug discovery and development,"  said Ted Jing, ReviR board member and 5Y Capital managing director. "RNA-focused therapeutics is a new but exciting area.  I believe the drug discovery experience and technical knowhow of ReviR's team uniquely positions them to fully explore this new opportunity." 

"The drug discovery and development process is becoming more data-centric especially in this new era of RNA-targeting therapeutics," said Dan Liu, partner of CDH Investments. "The founding team of ReviR has broad experiences in the fields of RNA biology and AI. We are confident that ReviR will become a world-leading RNA technology company and discover treatments for challenging human diseases by focusing on RNA."